Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | S100A4 | P26447 | 1/20 | 0.39 |
| ▸ | CUL4A | Q13619 | 1/20 | 0.39 |
| ▸ | VCAM1 | P19320 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL618153 | 0.86 | TDP1 (0.54) | TDP1GPR35ALDH1A1HPGDTSHR | |
| SCHEMBL30694393 | 0.79 | VCAM1 (0.47) | TDP1GPR35ALDH1A1HPGDTSHR | |
| SCHEMBL220318 | 0.79 | VCAM1 (0.47) | TDP1GPR35ALDH1A1HPGDTSHR | |
| SCHEMBL2950121 | 0.78 | VCAM1 (0.50) | TDP1GPR35ALDH1A1HPGDTSHR | |
| SCHEMBL21957846 | 0.78 | VCAM1 (0.50) | TDP1GPR35ALDH1A1HPGDTSHR | |
| SCHEMBL621936 | 0.78 | GPR35 (0.56) | TDP1GPR35ALDH1A1HPGDHSD17B10 | |
| SCHEMBL700631 | 0.78 | TSHR (0.58) | TDP1GPR35ALDH1A1HPGDTSHR | |
| SCHEMBL16959740 | 0.78 | TDP1 (0.45) | TDP1GPR35ALDH1A1HPGDTSHR | |
| SCHEMBL2413571 | 0.78 | SMN1; SMN2 (0.46) | TDP1GPR35ALDH1A1HPGDTSHR | |
| SCHEMBL1850626 | 0.78 | ALDH1A1 (0.47) | TDP1GPR35ALDH1A1HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107365319-B | Modulation of chemosensory receptors and ligands associated therewith | 弗门尼舍公司 | 2020-10-27 | — | — | CN | disclosed |
| CN-110115365-A | The adjusting that actinism receptor and relative ligand are carried out | 西诺米克斯公司 | 2019-08-13 | — | — | CN | disclosed |
| EP-2573559-B1 | Modulation of chemosensory receptors and ligands associated therewith | SENOMYX INC (US) | 2019-03-13 | — | — | EP | disclosed |
| CN-101779124-B | Modulation of chemosensory receptors and ligands associated therewith | 西诺米克斯公司 | 2017-12-12 | — | — | CN | disclosed |
| CN-107365319-A | The regulation carried out to actinism acceptor and relative part | 西诺米克斯公司 | 2017-11-21 | — | — | CN | disclosed |
| EP-2062050-B1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | SENOMYX INC (US) | 2016-05-18 | — | — | EP | disclosed |
| US-9181276-B2 | Modulation of chemosensory receptors and ligands associated therewith | SENOMYX, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140235623-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | SENOMYX, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8633186-B2 | Modulation of chemosensory receptors and ligands associated therewith | SENOMYX INC. (US) | 2014-01-21 | — | — | US | disclosed |
| EP-2573559-A1 | Modulation of chemosensory receptors and ligands associated | Senomyx, Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| EP-2568287-A2 | Modulation of chemosensory receptors and ligands associated | Senomyx, Inc. (US) | 2013-03-13 | — | — | EP | disclosed |
| US-20110224155-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | SENOMYX INC. (US) | 2011-09-15 | — | — | US | disclosed |
| CN-101779124-A | modulation of chemosensory receptors and ligands associated therewith | SENOMYX INC | 2010-07-14 | — | — | CN | disclosed |
| EP-2062050-A2 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | Senomyx, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008154221-A2 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | SENOMYX, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235623-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | TAS2R30, TAS2R50, TAS2R1 | TDP1 4142/4885GPR35 204/4885ALDH1A1 4242/4885 |
| US-20110224155-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | TAS2R30, TAS2R50, TAS2R1 | TDP1 4142/4885GPR35 204/4885ALDH1A1 4242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.